Evaluation of VLA-4 (Integrin α4β1) as a Shared Target for Radiopharmaceutical Therapy across Solid Tumors.

ABSTRACT: Radiopharmaceutical therapy (RPT) is a promising approach to treating solid tumors, but therapeutic advances are impeded by the lack of broadly expressed targets and shared molecular vulnerability across different tumor types. Here, we evaluate VLA-4 (integrin α4β1) as a potential target for RPT in solid tumors and use radiolabeled copper-64 ([64Cu]Cu-) and copper-67 ([67Cu]Cu-CB-TE1A1P-PEG4-LLP2A) LLP2A, a peptidomimetic ligand of VLA-4, for preclinical imaging and RPT testing. Expression of ITGA4, the gene encoding the alpha 4 subunit (CD49d) of VLA-4, was evaluated in a variety of cancer tissues from publicly available datasets. VLA-4 protein expression was determined by flow cytometry in 22 different human and murine cancer cell lines. We used orthotopic syngeneic (i.e., B16-F10, B78,

SUBMITTER: Reyes-Gonzalez JM 

PROVIDER: S-EPMC12137001 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature